Bradycardia

Remimazolam as an Alternative to Propofol in Oral Surgeries

Retrieved on: 
Monday, January 29, 2024

LAWRENCE, Kan., Jan. 29, 2024 /PRNewswire-PRWeb/ -- Anesthesia Progress – Propofol has been a widely used intravenous sedative for oral and maxillofacial surgeries because of advantages like less postoperative nausea and vomiting (PONV), no air pollution issues, a fast, clean emergence profile, and less emergence delirium. However, propofol has some significant downsides, including cardiovascular depression, injection pain, high fat content, and not being water-soluble. Recently, remimazolam has been suggested as an alternative to propofol in dental procedures because it does not contain similar fat, does not cause injection pain, and does not have cardiovascular depression potential. But is remimazolam as safe and effective as propofol?

Key Points: 
  • Recently, remimazolam has been suggested as an alternative to propofol in dental procedures because it does not contain similar fat, does not cause injection pain, and does not have cardiovascular depression potential.
  • The results of this study show that remimazolam could be considered a suitable alternative to propofol.
  • They go on to note that "remimazolam appears to be a safe alternative to propofol for providing intubated general anesthesia for oral and maxillofacial surgery procedures."
  • Full text of the article, "Comparison of Remimazolam and Propofol for Intubated General Anesthesia for Oral and Maxillofacial Surgery," Anesthesia Progress, Vol.

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Retrieved on: 
Monday, January 8, 2024

AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure.

Key Points: 
  • AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure.
  • Orchestra BioMed and Medtronic, Inc. (NYSE: MDT) (“Medtronic”) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022.
  • Orchestra BioMed is actively screening patients for enrollment in the BACKBEAT pivotal study.
  • The study will randomize approximately 500 patients 1:1 to AVIM therapy combined with continued medical therapy (treatment) or continued medical therapy and standard pacing alone (control).

Spinal Cord Injury Market Likely to Exhibit Substantial Growth by 2032, Assesses DelveInsight | Companies to Watch Out - NervGen Pharma, StemCyte, Mitsubishi Tanabe Pharma America, AbbVie

Retrieved on: 
Wednesday, November 1, 2023

LAS VEGAS, Nov. 1, 2023 /PRNewswire/ -- DelveInsight's Spinal Cord Injury Market Insights report includes a comprehensive understanding of current treatment practices, spinal cord injury emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • Leading spinal cord injury companies such as NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others are developing novel spinal cord injury drugs that can be available in the spinal cord injury market in the coming years.
  • Spinal cord injury represents a significant medical condition that results in a wide range of functional, psychological, and socioeconomic challenges.
  • The spinal cord injury epidemiology section provides insights into the historical and current spinal cord injury patient pool and forecasted trends for individual seven major countries.
  • To know more about spinal cord injury treatment, visit @ Spinal Cord Injury Treatment Drugs
    Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc.
    MT-3921: Mitsubishi Tanabe Pharma America Inc.

Spinal Cord Injury Market Likely to Exhibit Substantial Growth by 2032, Assesses DelveInsight | Companies to Watch Out - NervGen Pharma, StemCyte, Mitsubishi Tanabe Pharma America, AbbVie

Retrieved on: 
Wednesday, November 1, 2023

LAS VEGAS, Nov. 1, 2023 /PRNewswire/ -- DelveInsight's Spinal Cord Injury Market Insights report includes a comprehensive understanding of current treatment practices, spinal cord injury emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • Leading spinal cord injury companies such as NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others are developing novel spinal cord injury drugs that can be available in the spinal cord injury market in the coming years.
  • Spinal cord injury represents a significant medical condition that results in a wide range of functional, psychological, and socioeconomic challenges.
  • The spinal cord injury epidemiology section provides insights into the historical and current spinal cord injury patient pool and forecasted trends for individual seven major countries.
  • To know more about spinal cord injury treatment, visit @ Spinal Cord Injury Treatment Drugs
    Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc.
    MT-3921: Mitsubishi Tanabe Pharma America Inc.

Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies

Retrieved on: 
Monday, October 16, 2023

CHESTERBROOK, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported topline safety and tolerability data for the two Phase 1 proof-of-concept (POC) studies of TRV045, a novel sphingosine-1 phosphate receptor modulator selective for the S1P receptor subtype 1.   

Key Points: 
  • Each subject received three different single doses of TRV045 (50mg, 150mg and 300mg) and placebo on four separate visits across the study duration.
  • Subjects in both studies were enrolled outside of the United States, and the studies were not conducted under the Investigational New Drug Application for TRV045.
  • This new safety and tolerability data in 50 subjects is generally consistent with, and further builds upon, the 89-subject data from the first-in-human study of TRV045 reported in November 2022.
  • “We are pleased to report additional safety and tolerability data which is consistent with what we have observed in prior datasets,” said Carrie Bourdow, President and CEO of Trevena.

Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis

Retrieved on: 
Monday, October 9, 2023

SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced positive results from the Phase 2 trial of VTX002, a novel oral S1P1 receptor modulator, in patients with moderate-to-severely active ulcerative colitis (UC).

Key Points: 
  • The Phase 2 trial of VTX002 was a 13-week, randomized, double-blind, placebo-controlled, dose-ranging trial evaluating the efficacy and safety of two oral doses of VTX002 (30 mg and 60 mg once daily) in patients with moderate-to-severely active UC.
  • The primary endpoint was the proportion of patients achieving clinical remission at Week 13 as defined by the modified Mayo Clinic Score.
  • I am excited to see the positive results from the VTX002 Phase 2 trial.” Dr. Sands is the primary investigator for this trial, and a paid consultant for Ventyx Biosciences, Inc. with stock and stock options in the company.
  • ET to discuss the results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active UC.

Missing Dog Found High on Pot Brownies

Retrieved on: 
Wednesday, October 11, 2023

MINNEAPOLIS, Oct. 11, 2023 /PRNewswire/ -- When your pet goes missing, panic sets in. Did someone take them? Were they hit by a car? Are they safe? For Jake Carrigan of Hutchinson, Minn., his missing dog story is more like an old Cheech and Chong comedy bit, except it could have had a tragic ending.

Key Points: 
  • For Jake Carrigan of Hutchinson, Minn., his missing dog story is more like an old Cheech and Chong comedy bit, except it could have had a tragic ending.
  • "I was at work and my brother texted me to ask if my dog Dozer had gotten out of the house," Carrigan recalled.
  • I had him send me the post, and I drove to where the person had seen the dog, but I couldn't find him."
  • I asked my neighbor who I suspect might indulge in such brownies, and he said they didn't come from his house."

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Retrieved on: 
Tuesday, September 19, 2023

Orchestra BioMed and Medtronic plc (NYSE: MDT) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022.

Key Points: 
  • Orchestra BioMed and Medtronic plc (NYSE: MDT) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022.
  • Under the collaboration, Medtronic is providing Orchestra BioMed with development, clinical, and regulatory support for the BACKBEAT global pivotal study, which Orchestra BioMed is sponsoring.
  • Orchestra BioMed will share in the revenues generated from Medtronic sales of the AVIM-enabled pacing systems.
  • “We are thrilled to receive IDE approval from the FDA and move forward with plans to initiate the BACKBEAT global pivotal study, which is designed to support potential future regulatory review and potential approval of AVIM therapy for hypertensive patients indicated for a pacemaker.

FIGS and Eko Health Collaborate on the FIGS | Eko CORE 500™ Digital Stethoscope

Retrieved on: 
Tuesday, September 5, 2023

FIGS, Inc. (NYSE: FIGS), the direct-to-consumer healthcare apparel and lifestyle brand, and Eko Health, Inc. (“Eko”), a leading innovator in digital health technology for heart and lung disease detection, today announced the launch of the FIGS | Eko CORE 500™ Digital Stethoscope.

Key Points: 
  • FIGS, Inc. (NYSE: FIGS), the direct-to-consumer healthcare apparel and lifestyle brand, and Eko Health, Inc. (“Eko”), a leading innovator in digital health technology for heart and lung disease detection, today announced the launch of the FIGS | Eko CORE 500™ Digital Stethoscope.
  • “We are thrilled to be partnering with Eko to bring the CORE 500™ Digital Stethoscope to our amazing healthcare community,” said Trina Spear, CEO and Co-Founder of FIGS.
  • Joining forces on the FIGS | Eko CORE 500™ Digital Stethoscope will support clinicians, advance the future of cardiovascular care, and benefit millions of patients.”
    The FIGS | Eko CORE 500™ Digital Stethoscope is available exclusively at www.wearfigs.com and through the FIGS App for sale in the United States.
  • All editions of the CORE 500™ Digital Stethoscope, first launched by Eko in June 2023, are for healthcare professional use only.

Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.

Retrieved on: 
Thursday, August 10, 2023

Dr. Reddy’s Saxagliptin and Metformin Hydrochloride Extended-Release Tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30.

Key Points: 
  • Dr. Reddy’s Saxagliptin and Metformin Hydrochloride Extended-Release Tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30.
  • Please click here to see the full prescribing information, including boxed warning: https://drreddys.com/pil/150092247-PIL-Saxagl-Met-HCL-ER-Tab-US_V3_fn.pdf .
  • Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL.
  • (5.1)
    If lactic acidosis is suspected, discontinue saxagliptin and metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting.